Aspen offers excessive-pricing commitments
Aspen has said it will reduce its prices for six cancer drugs in Europe by an average of 73%, as part of a commitment package seeking to end the EU antitrust watchdog’s first excessive-pricing investigation in the pharmaceutical sector.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10